Invesco Ltd. Buys 3,505,828 Shares of Hologic, Inc. $HOLX

Invesco Ltd. raised its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 72.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,340,785 shares of the medical equipment provider’s stock after purchasing an additional 3,505,828 shares during the quarter. Invesco Ltd. owned approximately 3.75% of Hologic worth $543,486,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. United Services Automobile Association bought a new position in shares of Hologic in the 1st quarter worth approximately $347,000. K.J. Harrison & Partners Inc purchased a new stake in Hologic in the second quarter worth $1,987,000. Aberdeen Group plc raised its holdings in Hologic by 2.8% in the second quarter. Aberdeen Group plc now owns 244,997 shares of the medical equipment provider’s stock worth $15,964,000 after purchasing an additional 6,589 shares in the last quarter. Nordea Investment Management AB lifted its position in Hologic by 7.2% during the second quarter. Nordea Investment Management AB now owns 2,587,414 shares of the medical equipment provider’s stock valued at $168,674,000 after buying an additional 174,828 shares during the period. Finally, Carnegie Investment Counsel boosted its holdings in shares of Hologic by 10.6% during the 2nd quarter. Carnegie Investment Counsel now owns 221,528 shares of the medical equipment provider’s stock valued at $14,435,000 after buying an additional 21,273 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Hologic news, Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $73.07, for a total value of $540,864.14. Following the transaction, the director directly owned 47,336 shares in the company, valued at approximately $3,458,841.52. This trade represents a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their position. The SEC filing for this sale provides additional information. 1.88% of the stock is currently owned by corporate insiders.

Hologic Stock Down 0.2%

HOLX stock opened at $74.86 on Friday. The company has a market cap of $16.69 billion, a price-to-earnings ratio of 30.19, a P/E/G ratio of 2.14 and a beta of 0.70. The company has a debt-to-equity ratio of 0.50, a quick ratio of 3.06 and a current ratio of 3.75. The business’s 50-day moving average is $72.12 and its two-hundred day moving average is $67.47. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $80.31.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating the consensus estimate of $1.10 by $0.03. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same quarter in the prior year, the firm earned $1.01 EPS. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Wall Street Zen lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a report on Friday, October 31st. BNP Paribas downgraded Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a report on Friday, November 21st. Mizuho downgraded shares of Hologic from an “outperform” rating to a “neutral” rating and increased their price objective for the company from $70.00 to $78.00 in a research report on Thursday, October 23rd. Finally, BNP Paribas Exane lowered Hologic from an “outperform” rating to a “neutral” rating and set a $79.00 target price for the company. in a report on Friday, November 21st. Five research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $79.67.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.